The relative cost-effectiveness of proton-pump inhibitors (PPIs) in the maintenance therapy of erosive @entity354 was studied. Decision analysis was used to model the cost-effectiveness of PPIs on the basis of clinical trial results. Management decisions in the model were based on published U.S. guidelines and recommendations. Probability estimates were derived from a systematic review of the literature. The model's base-case scenario compared @entity7619 , @entity10042 , and @entity4546 for the prevention of symptom recurrence over one year. Meta-analyzed estimates of efficacy were derived from trials by using a generalized logistic regression model with random effects. Medical costs for hospitalization, procedures, and office visits reflected 2000 Medicare payment; drug costs were based on 2000 average wholesale prices. Average costs per @entity1 were comparable among the PPIs ( @entity7619 ,  1414; @entity10042 ,  1671; and @entity4546 ,  1599). @entity7619 prevented symptom recurrence in 86% of @entity7619 recipients, versus 68% for @entity10042 and 81% for @entity4546 , and yielded the lowest average cost-effectiveness ratio ( @entity7619 ,  1637 per recurrence prevented; @entity10042 ,  2439; and @entity4546 ,  1968). The model was robust to changes in key variables. When evaluated by decision analysis over a wide range of assumptions, @entity7619 was comparable to other PPIs in terms of cost and offered improved effectiveness for maintenance therapy of erosive @entity354 .

Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive XXXX .

@entity1 :: ('9606', 'Species') :: ['patient'] @entity7619 :: ('MESH:C063129', 'Chemical') :: ['Rabeprazole', 'rabeprazole'] @entity10042 :: ('MESH:C058687', 'Chemical') :: ['lansoprazole'] @entity354 :: ('MESH:D005764', 'Disease') :: ['reflux esophagitis'] @entity4546 :: ('MESH:D009853', 'Chemical') :: ['omeprazole']
@entity354 :: (MESH:D005764,Disease) :: ['reflux esophagitis']
